Abatacept is second to rituximab at risk of HBsAg reverse seroconversion in patients with rheumatic disease
| Autor: | I-Cheng Lee, Ming-Han Chen, Ming-Chih Hou, Chang Youh Tsai, Ming-Huang Chen, Yi Hsiang Huang |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Adult
Male HBsAg medicine.medical_specialty Immunology medicine.disease_cause Gastroenterology General Biochemistry Genetics and Molecular Biology Abatacept Arthritis Rheumatoid 03 medical and health sciences Hepatitis B Chronic 0302 clinical medicine Rheumatology Antigen Internal medicine medicine Humans Immunology and Allergy Hepatitis B Antibodies Aged 030203 arthritis & rheumatology Hepatitis B virus Hepatitis B Surface Antigens biology business.industry virus diseases Middle Aged Hepatitis B medicine.disease digestive system diseases Seroconversion Antirheumatic Agents Reinfection Rheumatoid arthritis biology.protein Female 030211 gastroenterology & hepatology Rituximab Antibody business medicine.drug |
| Zdroj: | Annals of the Rheumatic Diseases. 80:1393-1399 |
| ISSN: | 1468-2060 0003-4967 |
| Popis: | BackgroundHepatitis B surface antigen (HBsAg) reverse seroconversion (RS) can happen in patients with rheumatoid arthritis (RA) with resolved hepatitis B (RHB) undergoing biological disease-modifying antirheumatic drugs (bDMARDs). But the incidence and risk factors need to be delineated.MethodsFrom 2003 to 2019, 1937 patients with RA with available HBsAg and antibody to hepatitis B virus (HBV) core antigen data were retrospectively reviewed, and 489 patients with RHB undergoing bDMARDs treatment were identified. Factors associated with HBsAg RS were analysed.ResultsDuring 67 828 person-months of follow-up, 27 (5.5%) patients developed HBsAg RS after bDMARD treatment. As compared with those without HBsAg RS, patients with HBsAg RS were older, had lower frequency of antibody to HBsAg (anti-HBs), and lower baseline anti-HBs levels. In multivariate analysis, rituximab, abatacept and baseline negative for anti-HBs were the independent risk factors for HBsAg RS (adjusted HR: 87.76, 95% CI: 11.50 to 669.73, pConclusionsNot only rituximab, but also abatacept has a high risk of HBV reactivation in patient with RA with RHB. Anti-HBs positivity cannot confer HBV reactivation-free status if the anti-HBs levels are not high enough for patients with RHB on rituximab and abatacept treatment. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|